PHARMA PRODUCTION AS

Operating

Produksjon, pakking og ompakking av farmasøytiske produkter, herunder legemidler, samt aktiviteter og investeringer som vil være formålstjenlig med slik virksomhet.

Produksjon av registrerte reseptpliktige legemidler, samt ompakkingsoppdrag av legemidler. Produksjon og ompakking foretas til legemiddelselskap som eier markedsføringstillatelse av legemidlene i Norge og øvrige nordiske land.

Keywords

productionpharmaceuticalsantiserablood fractionsvaccineshomeopathic preparationscontraceptive productsbone buildingdiagnostic preparationspregnancy testsbiotechnological medicinescotton woolgasbandagesdressings

Organization

Chairman of the board: GO
Geir Ove Engeset1972
Years since formation: 9 years; since Dec 11, 2017
Type: Limited company
VAT registered: Yes
Number of employees: 17

Ownership

Number of shares and share classes: 300,000; 1 share class
Total number of shareholders: 1; company
Belongs to group of

Financials

Total operating income 2025: 32,694,973; NOK
Annual total result 2025: -4,324,877; NOK
Total equity 2025: 3,005,580; NOK

Last update: Aug 22, 2026

Management

Board

Name	Role	Shares
GO Geir Ove Engeset 1972	Chairman	21.09 % indirectly
EE Esther Elisabeth Paust 1959	Board Member	23.05 % indirectly

Others

Name	Role	Shares
H HØILUND REVISJON AS	Auditor	-

Top 10 individual shareholders

Name	Role	Shares
EE Esther Elisabeth Paust 1959	Board Member	23.05 % indirectly
GO Geir Ove Engeset 1972	Chairman	21.09 % indirectly
FL Frode Lervik 1967	-	1.78 % indirectly
EF Erik Flatmark 1962	-	1.32 % indirectly
TC Theresa Comiskey Olsen 1963	-	1 % indirectly

Last update: Oct 24, 2023

Ownership

Company shareholders

Name	Share class	Total number of shares	Share
D DNE PHARMA AS	Ordinary shares	300,000	100 %

Last update: Jun 2, 2025

Group structure

FARMA INVESTMENT AS
Total operating income 2025: NOK 0
Operating profit 2025: NOK -1,521,611
Employees: 0

Financials

in NOK

Summary

Year	2025	2024	2023	2022	2021
Total operating income	32,694,973	29,405,048	21,361,765	19,798,251	17,459,417
Annual Total Result	-4,324,877	-3,588,723	-1,185,263	-7,078,525	-5,350,453
Total assets	27,214,886	20,050,887	15,450,074	23,617,767	11,342,915
Total liabilities	24,209,306	19,585,921	11,396,385	18,378,815	11,025,438
Total equity	3,005,580	464,966	4,053,689	5,238,952	317,477

P&L

Year	2025	2024	2023	2022	2021
Total operating income	32,694,973	29,405,048	21,361,765	19,798,251	17,459,417
Total operating costs	35,884,719	33,240,243	29,288,609	26,237,503	22,253,343
Operating result	-3,189,746	-3,835,195	-7,926,844	-6,439,252	-4,793,926
Financial income/costs	-1,264,701	-765,734	-1,074,113	-639,272	-556,527
Profit before tax	-4,454,447	-4,600,928	-9,000,957	-7,078,525	-5,350,453
Total tax & extraordinary income/cost	-129,570	-1,012,205	-7,815,694	0	0
Annual Total Result	-4,324,877	-3,588,723	-1,185,263	-7,078,525	-5,350,453

Balance overview

Year	2025	2024	2023	2022	2021
Total fixed assets	9,629,507	9,386,815	8,547,932	522,286	717,474
Total current assets	17,585,380	10,664,072	6,902,142	23,095,481	10,625,440
Total assets	27,214,886	20,050,887	15,450,074	23,617,767	11,342,915
Short term debt	24,209,306	19,585,921	11,396,385	18,378,815	11,025,438
Long term debt	0	0	0	0	0
Total liabilities	24,209,306	19,585,921	11,396,385	18,378,815	11,025,438
Contributed capital	316,930	316,930	316,930	316,930	316,930
Retained earnings	2,688,650	148,036	3,736,759	4,922,022	547
Total equity	3,005,580	464,966	4,053,689	5,238,952	317,477
Total equity and liabilities	27,214,886	20,050,887	15,450,074	23,617,767	11,342,915

Classification

21st company classification

BETA

Scaleup

PHARMA PRODUCTION AS920 049 060